Publications and Data Presentations
CRPC Preclinical Data Presentation AACR-NCI-EORTC 2019Nov, 2019
Interim Update From a Phase 2 Multicenter Study of Tazemetostat for FL Data Presentation ICML 2019Nov, 2019
Natural History Study Poster EHA 2019Jun, 2019
A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adults (Epithelioid Sarcoma Cohort) (NCT02601950)Oct, 2018
Interim Update of Tazemetostat in Follicular Lymphoma from Ongoing Phase 2 StudyJun, 2018
ASCO 2018 Mesothelioma PosterJun, 2018
ASH 2017 G9a PosterDec, 2017
Interim Efficacy and Safety Data of Tazemetostat in Follicular Lymphoma and DLBCL from Ongoing Phase 2 StudyJun, 2017
Preliminary Evidence of Molecular Predictors of Tazemetostat in NHLJun, 2017
Activity of EZH2 inhibitors as monotherapy and in combination with multiple myeloma therapiesApr, 2017
Tazemetostat Phase 1 NHL Update at ASH LymphomaJun, 2016 | ASH Lymphoma Biology
Tazemetostat Early Phase 2 NHL Study Findings Poster at ASH LymphomaJun, 2016 | ASH Lymphoma Biology
Tazemetostat Early Phase 2 NHL Study Findings at ASH LymphomaJun, 2016 | ASH Lymphoma Biology
Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor Pinometostat (EPZ-5676) in Children with MLL-r Acute Leukemia: Safety, Exposure and Evidence of Target InhibitionDec, 2015
Identification of biomarkers and pathways associated with response to DOT1L inhibitor Pinometostat (EPZ-5676) in MLL-r leukemiaNov, 2015
Pinometostat, EPZ-5676, Enhances the Anti-Proliferative Activity of MAP Kinase Pathway Inhibitors in Cell Lines Less Sensitive to DOT1L inhibitionNov, 2015
EZH2 plays a critical role in B-cell maturation and in non-Hodgkin’s lymphoma: Interplay between EZH2 function and B-cell activationNov, 2015
CRISPR Pooled Screening Identifies Differential Dependencies on Epigenetic PathwaysNov, 2015
A Medium-Throughput Single Cell CRISPR/Cas9 Assay to Assess Gene EssentialityNov, 2015
Identification of a First-In-Class PRMT5 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Mantle Cell LymphomaDec, 2014 | ASH
Preclinical Evaluation of EZH2 Inhibitors in Models of Human Synovial SarcomaOct, 2014
Small Molecule Control of Chromatin RemodelingSep, 2014 | Chemistry & Biology Review
DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia CellsJul, 2014 | Journal of Pharmacology and Experimental Therapeutics
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 Mutant Non-Hodgkin LymphomaFeb, 2014 | Molecular Cancer Therapeutics
EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies in Preclinical ModelsDec, 2013 | ASH
Potent inhibition of DOT1L as a treatment for MLL-fusion leukemiaAug, 2013 | Blood
Epizyme® announces that the “Nature Reprint Collection: Epigenetics” from Nature Publishing Group is now available onlineMay, 2013 | Nature Reprint Collection
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2Mar, 2013 | PNAS
Chemogenetic analysis of human protein methyltransferasesJun, 2011 | Chemical Biology & Drug Design
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomasOct, 2010 | PNAS
Epizyme Scientific Publications ReferenceJan, 2008